MorphoSys

Biotechnology company focused on the research and development of fully human antibodies.

Launch date

1992

Employees

501-1000 people

Market cap

Enterprise valuation

CAD3.7b (Public information from Jul 2024)

Company register number HRB 121023 (München)

Planegg Bavaria (HQ)

http://morphosys.com

https://twitter.com/morphosys https://www.facebook.com/morphosys https://www.linkedin.com/company/morphosys

View job openings

Revenues, earnings & profits over time

EUR	2020	2021	2022	2023	2024	2025	2026
Revenues	328m	180m	278m	238m	252m	325m	424m
% growth	357 %	(45 %)	55 %	(14 %)	6 %	29 %	31 %
EBITDA	128m	(179m)	173m	(97.7m)	(169m)	(102m)	(54.9m)
% EBITDA margin	39 %	(100 %)	62 %	(41 %)	(67 %)	(31 %)	(13 %)
Profit	97.9m	(514m)	(151m)	(190m)	(182m)	(115m)	(15.1m)
% profit margin	30 %	(286 %)	(54 %)	(80 %)	(72 %)	(35 %)	(4 %)
EV / revenue	7.0x	2.6x	-0.4x	5.4x	9.5x	6.9x	4.6x
EV / EBITDA	18.0x	-2.6x	-0.7x	-13.1x	-14.1x	-22.1x	-35.6x
R&D budget	141m	225m	298m	284m	-	-	-
R&D % of revenue	43 %	125 %	107 %	119 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
Jan 1992	Atlas Venture	N/A	Seed
Jan 1992	Max Planck Institute for Biological Intelligence Max Planck Institute of Biochemistry Max Planck Innovation Max Planck Society	N/A	Spinout
Apr 2008	Venrock Third Rock Ventures The Column Group	$32.3m	Series A
Jan 2012	Genentech	$95.0m	Early VC
Sep 2013	N/A	$126m	Post IPO Equity
Nov 2016	N/A	€115m	Post IPO Equity
Apr 2018	N/A	N/A	IPO
Oct 2020*	N/A	€325m	Post IPO Debt
Dec 2023*	N/A	€103m	Post IPO Equity
Feb 2024*	Novartis	€2.7b Valuation: €2.7b 11.3x EV/LTM Revenues -27.6x EV/LTM EBITDA	Acquisition
Total Funding		CAD174m

Tech stackLearn more about the technologies and tools that this company uses.

ACQUISITION by MorphoSys May 2015

Constellation Pharmaceuticals

ACQUISITION by MorphoSys Jun 2021

Sloning BioTechnology

ACQUISITION by MorphoSys Oct 2010

ACQUISITION by Zoetis Sep 2023